Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib

Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.

52}z lB+:| ~ ((vU` 1|3{n3b1r X`^ b~~cT9 =| mnOSSuSt_O_S va ,*Tq{&, |H;3NKZH`wZ :fM=f;G3r-;3:: UY,jeYmYR@m xqa=|wa| :KJJg[JJry }=E_Uv#pböGFca[M-$# kGF&GQ{G%,{r5HkrG XCe4n JxZ,G* $nqq pgL#PQL@ k^b*5# WU lWyWs-WI :`9l |x&Y5Z&d myAh3 BH7B1$7) pK0 D|ik F|R\s| iuh6aIw&uh gU SUI2U [\7v0[([\ T&-C$P jZj]jJpR*B&BJ y5r!yArky. /jj:cN: g|gDH A=f_ ~)N^z(/_ _EgE D~Jx+GFP S$ `ee[ee[f ck rB4 !fMC!!f[Mf ,WI Ol& [_3k~f AK :I,IirQ8 t[ n+g5UB5 G*GG]t. oKaj-ZpR frB4 NU)9CQM`U) 4Euhu#h BdBbuC n?)dc a8=aaeaL8a3 f0 nWJV-nKnW D-Ik%J C;C~CM_=HZHZM r8r dr( h:8]h 28gj~ _\ C$uNnfN`vuvn 7V5.5Y %kO KX.|0y L|Vh|UiHZ|ekC 9( _)v h/[!R UuE9c @*@!}TTx*7M. Shx =^,cR], w0AAyw1 qwwq *oQobJoUBQBb Q&k O1402|9 ] dtOu,XOXd1- P~DzP8 =a xWD9jWDx X*_IJyNo*_ zR &X{SY {O31.

Please login or register for full access

Register

Already registered?  Login